Takeda's Brintellix Edges Closer To Cognitive Effects Labeling Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisors support language on improved cognitive effects in major depressive disorder, but worry about precedent for other antidepressants and advertising implications.